Director Stephen K. Brannan buys 1,000 Serina Therapeutics (SER) shares at $2.03
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Serina Therapeutics, Inc. director Stephen K. Brannan reported an open-market purchase of common stock. On July 7, 2026, he bought 1,000 shares of Serina Therapeutics common stock at a price of $2.03 per share. After this transaction, he directly holds 1,000 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 1,000 shares ($2,030)
Net Buy
1 txn
Insider
Brannan Stephen K.
Role
null
Bought
1,000 shs ($2K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 1,000 | $2.03 | $2K |
Holdings After Transaction:
Common Stock — 1,000 shares (Direct, null)
Footnotes (1)
Key Figures
Shares purchased: 1,000 shares
Purchase price: $2.03 per share
Shares owned after transaction: 1,000 shares
3 metrics
Shares purchased
1,000 shares
Open-market purchase of common stock on July 7, 2026
Purchase price
$2.03 per share
Price paid for Serina Therapeutics common stock
Shares owned after transaction
1,000 shares
Total direct holdings by Stephen K. Brannan after trade
Key Terms
open-market purchase, Common Stock, Form 4
3 terms
open-market purchase financial
"transaction_action: open-market purchase"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
Common Stock financial
"security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
What insider transaction did Serina Therapeutics (SER) report?
Serina Therapeutics reported that director Stephen K. Brannan purchased 1,000 shares of common stock. The open-market transaction occurred on July 7, 2026 at $2.03 per share, and reflects a direct increase in his personal shareholdings.
What is Stephen K. Brannan’s Serina Therapeutics (SER) ownership after the trade?
After the reported open-market purchase, Stephen K. Brannan directly owns 1,000 Serina Therapeutics shares. The Form 4 indicates this post-transaction total, with all reported holdings in the company’s common stock classified as direct ownership.
Was the Serina Therapeutics (SER) insider transaction a buy or a sell?
The Serina Therapeutics insider transaction was a buy. The Form 4 lists a transaction code P, described as an open-market purchase, where director Stephen K. Brannan acquired 1,000 shares of common stock at $2.03 per share.